Adherex Technologies (FENC)
(Delayed Data from NSDQ)
$6.78 USD
-0.07 (-1.02%)
Updated May 31, 2024 04:00 PM ET
After-Market: $6.79 +0.01 (0.15%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.78 USD
-0.07 (-1.02%)
Updated May 31, 2024 04:00 PM ET
After-Market: $6.79 +0.01 (0.15%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Zacks News
Adherex Technologies Inc. (FENC) Lags Q1 Earnings Estimates
by Zacks Equity Research
Adherex Technologies (FENC) delivered earnings and revenue surprises of -16.33% and 142.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 1.74% and 223.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 0% and 10.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Xencor (XNCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Xencor (XNCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Adherex Technologies Inc. (FENC) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Adherex Technologies (FENC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adherex Technologies (FENC) delivered earnings and revenue surprises of -600% and 2.80%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Fennec (FENC) Signs Licensing Deal With Norgine, Stock Up
by Zacks Equity Research
Fennec (FENC) signs a licensing deal with Nordine, granting the latter rights to Pedmarqsi in the EU, Australia and New Zealand to treat cisplatin-induced hearing loss. The stock rises 11.4%.
Adherex Technologies Inc. (FENC) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Adherex Technologies Inc. (FENC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Wall Street Analysts See a 64.61% Upside in Adherex Technologies Inc. (FENC): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 64.6% upside potential for Adherex Technologies Inc. (FENC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Recent Price Trend in Adherex Technologies Inc. (FENC) is Your Friend, Here's Why
by Zacks Equity Research
Adherex Technologies Inc. (FENC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Wall Street Analysts Think Adherex Technologies Inc. (FENC) Could Surge 81%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Adherex Technologies Inc. (FENC) points to an 81% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe Adherex Technologies Inc. (FENC) Could Rally 109.97%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 110% upside potential for Adherex Technologies Inc. (FENC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Adherex Technologies Inc. (FENC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of 36.36% and 24.90%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Adherex Technologies Inc. (FENC) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of -16.67% and 17.12%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Adherex Technologies Inc. (FENC) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of -9.52% and 10.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of -8.33% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Adherex Technologies (FENC)
by Zacks Equity Research
Adherex Technologies (FENC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Feneca (FENC) Gets FDA Nod for Cancer-Related Hearing Loss Drug
by Zacks Equity Research
Feneca Pharmaceuticals (FENC) receives FDA approval for Pedmark to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors.
Has Bellus Health (BLU) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Bellus Health (BLU) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.
Has Adherex Technologies (FENC) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Adherex Technologies Inc. (FENC) and U.S. Physical Therapy (USPH) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Bellus Health (BLU) This Year?
by Zacks Equity Research
Here is how Bellus Health (BLU) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.
Wall Street Analysts Predict an 80% Upside in Adherex Technologies Inc. (FENC): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Adherex Technologies Inc. (FENC) points to an 80.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Bellus Health (BLU) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Bellus Health (BLU) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.
Can Adherex Technologies Inc. (FENC) Climb 92% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in Adherex Technologies Inc. (FENC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Has Anixa Biosciences (ANIX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how ANIXA BIOSCIENCES INC (ANIX) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.